As a result, CNS indications such as brain disease in systemic lupus erythematosus (SLE) or multiple sclerosis where both macrophage and B cell biologies are implicated in disease pathogenesis may be alternative options for BTK inhibition. This evidence concerns the gene BTK and systemic lupus erythematosus.